NR2B-Selective NMDA Antagonists for Core ASD and OCD Symptoms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for autism spectrum disorders (ASDs), obsessive-compulsive disorder (OCD), and anxiety disorders are inadequate, with existing drugs displaying mixed results and significant side effects, failing to address the underlying causes and effectively alleviate behavioral and psychological symptoms.
Innovation Solution
The use of NR2B subunit-selective N-methyl-D-aspartate (NMDA) receptor antagonists, such as compounds of formula IA and IB, to treat ASDs, OCD, and anxiety disorders, targeting the underlying neuronal circuit abnormalities associated with these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current psychopharmacological agents are used to treat ASDs, then specific psychiatric or behavioral symptoms are addressed, but mixed results are obtained and significant side effects occur
Solution Approach 1:
The patent changes the pharmacological parameter from serotonin/dopamine system modulation to NMDA receptor antagonism, specifically targeting the NR2B subunit. This parameter change in mechanism of action provides reliable treatment efficacy for core ASD symptoms while minimizing side effects associated with traditional psychopharmacological agents
Solution Approach 2:
The patent introduces NMDA receptor antagonists as an intermediary substance that modulates glutamatergic transmission in the corticostriatal circuit. This intermediary acts on the underlying neuronal circuit abnormalities rather than directly suppressing symptoms, providing reliable treatment with better safety profile
2Reliability
If existing therapeutic strategies are used, then severe behavioral problems are targeted, but the underlying causes are not addressed and results are mixed
Solution Approach 1:
The patent applies preliminary action by targeting the underlying neuronal circuit abnormalities in the corticostriatal pathway before behavioral symptoms manifest. By modulating NMDA receptor function early in the pathophysiological cascade, the treatment addresses root causes rather than just symptoms, providing consistent therapeutic results
Solution Approach 2:
The patent extracts the treatment focus from superficial behavioral symptoms to the underlying neuronal circuit dysfunction. By isolating and targeting the specific NMDA receptor-mediated mechanisms in corticostriatal circuits, the invention addresses the root cause while filtering out ineffective symptomatic treatments
3Adaptability or versatility
If traditional psychopharmacological agents are administered, then various psychiatric symptoms are addressed, but no accepted rational therapeutic regimen exists for addressing autism or its causes
Solution Approach 1:
The patent applies universality by using a single class of agents (NMDA receptor antagonists) to treat multiple manifestations of ASD, including repetitive behaviors, social deficits, and anxiety. This multi-functional approach simplifies the therapeutic regimen while maintaining broad treatment coverage across diverse ASD symptoms
Solution Approach 2:
The patent segments the complex therapeutic need into a specific targetable mechanism: NMDA receptor-mediated glutamatergic transmission in corticostriatal circuits. By dividing the treatment approach into this specific neurobiological pathway, the invention creates a rational, structured regimen that addresses the complexity of ASD through targeted intervention
Data Source
AI summary
Disclosed are methods for treating NMDA receptor-mediated disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. NMDA receptor-mediated disorders include autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders.